August 06, 2026

BioPharmGuyNews.png

BioPharmGuy

Today is the day. Kids go back to school here in Indiana. After having been behind pretty much all summer I will suddenly be caught up on everything in about six days. Always nice.


Negging for Dollars

“Took a look at BioPharmGuy's site, it's dense and cluttered with no clear starting point for a first-time visitor. For "the premier resource for worldwide biotech company data," it looks more like a spreadsheet turned into a page than something built to convert.”


Wow, what a sales pitch!


I don’t profess to have the perfect website here, but the landing page has a big image telling you we have biotech company data. Then it says, "Who We Help" and there is a list of six types of people we help and how.


I will accept arguments about the beauty of the website. But to say I don’t clearly indicate what the website is and does is absurd.


-BPG


Companies Added & Removed

This week we added 28 companies and removed 57.


Best New Name:

Mandrake Bio


Worst New Name:

Magnendo


They Will Be Missed:

Glialign

Azora Therapeutics


They Won't Be Missed:

Purdue Pharma


Subscribe to our weekly update to receive a list of all companies added each week plus funding details and more.

Industry

Mega Merger

The industry was atwitter with talk of AstraZeneca and BMS merging. Stock prices dropped on the initial news, then jumped when the rumors were denied.


Investors do not seem to be interested in a deal of this size. If it did go through it would create a top 5 colossus.


Rumors like these don't generally come from nowhere, so we will keep our eyes on the situation.


Would be rough to see a merger like this vaporize another 20,000 biopharma jobs.


Cash for Dash 

Dash Bio, a noted BioPharmGuy Premium Listing client, has kept their string of success going, this time with a $30M Series A. They've taken the unique path of actually improving how labs work instead of waving their hands and saying “AI” three times.


What’s more, they publish prices on their website. We approve!


Having been a BioPharmGuy client since before their company even launched, is it possible we played a tiny part in this success? Who could really say?


Their COO that’s who:


“Thanks for the support and marketing, it has been really effective and we are excited to keep it going.”


So, are you just gonna keep dumping money into AI advertising forever? Get back to the basics; 45,000 people use the BioPharmGuy directory each month to research biotech-related companies. Check out our ad options.


Oral Gummies

Oral gummies have long solved numerous problems.


Boredom. Nausea. Social anxiety.


Next up? Ebola.


DR Congo's regulatory agency has approved a Phase 2 trial of an oral gummy. Interestingly, this "gummy" does not need to be swallowed and is absorbed in the mouth.


No idea is too crazy for this Ebola outbreak that shows no signs of abating.


Backstock Images

When BioPharmGuy started up back in 2008, it used to be a virtual guarantee that Indian and Chinese companies exclusively used stock images of white Caucasians with occasional Hispanic and African ancestry people peppered in.


Back then, both Asian giants had immature biotech industries, and often tried to present themselves as being US/Europe-adjacent. But also, the readily available stock images in that era were mostly European and American.


It's very rare to see this happen in 2026, but every now and then we come across one. These people kind of don’t look real, but also don’t seem like they’re modern AI stuff.


They all look like professional models except that goofy looking dude in the back middle. What’s going on with that look on his face? Highly punchable.


Prayers, Not Thoughts

Failing phase 3 used to be the end of the line for a potential drug, but companies have been insisting that isn’t true for some years now. Even if a product does eventually get approved post-failure, it can blow up spectacularly like Aduhelm which was ultimately withdrawn from the market by Biogen.


Gossamer Bio is the latest to refuse to read the writing on the wall and will hope the FDA is in an approval-happy mood when they check out the new drug application which includes a failed phase 3 trial.


Re-Petes

Keeping lizards as pets is fun. You can catch bugs, throw them in the cage and watch the lizards pounce.


You can also come up with cute names such as Toothless, Pascal or Scaly. Or Pete.


And if you're like the CEO of EpiCrispr, you can name all your lizards Pete.


Wonder what her husband Peter thinks of this tidbit.

Premium Listings drive traffic to your website and highlight your company for potential investors.


They will generally double or triple your referral rate. At $220/mo with a 3-month commitment, why not give it a trial?


Please send us a message if interested.

Health & Science

Mystery Patient

In April, a 79-year-old with high government connections was allowed to take an experimental Eli Lilly drug after a Senior Clinician at NIH requested it.


Considering the highest-ranking government official was 79 in April, people wondered if this special access was procured for President Trump himself. After some initial brush offs, his spokespeople said no, it was not him.


Whether that is factual or not, someone with government connections is getting preferred access to an experimental drug.


Historically, access like this was reserved for people who were terminally ill or had no hope of a decent life without some intervention. And the FDA had to approve every application.


In 2018, the Right-to-try legislation was enacted, which allowed companies to offer compassionate use drugs without FDA’s say-so.


It has been a slow roll-out since companies really don't like to give unapproved drugs to random people.


It may seem unfair that people with government connections can exert pressure on private companies to get access to unapproved experimental therapies, but don't forget they are not approved because nobody knows if they work. They could very well worsen people's health which is why they run the clinical trials.


Sounds Good

The head of the US NIH has released a new policy to stop high risk life science research, namely, the policy bans so-called “gain-of-function” research which is the concept of creating more deadly versions of existing pathogens. 


Call us crazy, but we thought that was pretty much banned by international treaties. Has the US government really been supporting the creation of deadly biological weapons all this time? If so, that's crazy.


By all means, go ahead and formally ban it. We can hope no one else is doing it!


(Spoiler: they are)


Culture Issues

The University of Utah had an issue in a biology lab class. The students were provided a bacterial sample and told to identify it.


100% identified it as Neisseria meningitidis which can cause meningitis.


The instructors checked it out and couldn't see why this work was incorrect. There was even a vial in the freezer labeled with that pathogen's name.


So, a massive biosafety incident ensued. Students were given antibiotics, some got spinal taps to test for meningitis, it was mayhem.


A state-run public health lab later ran some tests and concluded it was a related, non-pathogenic version that happened to have some weird traits that led everyone to misidentify it.


Oopsie!

Featured Job

Mispro has a brand new role as Marketing & Operations Lead. Remote, $85-95k/yr.


They seem to have a marketing budget too, so you'll probably have resources to actually do your job well.


How refreshing would that be?

Share!

Use this link to share on social platforms: View as Webpage


Subscribe!

If you haven't already, please join our mailing list.

BioPharmGuy is a registered trademark of Wilsonian LLC, Content © 2026 Wilsonian LLC